IDE

Across TCGA pan-cancer cohorts, IDE mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IDE data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IDE mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IDE expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where IDE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.952	0.760	.003	61	view →
UCEC	OS	Median	II,III,IV	1.000	0.659	.021	16	view →
LUAD	DFS	Tertile	All	0.407	0.911	.002	13	view →
GBM	DFS	Median	All	0.426	0.217	.013	8	view →
CCRCC	DFS	Tertile	III,IV	0.418	0.684	.033	4	view →
LSCC	DFS	Tertile	III,IV	1.000	0.691	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IDE–PDAC (OS)

Open the PDAC breakdown →